Physician profile
Robert J Long
NPI 1518174986
$633.93
in general payments reported to CMS, 2019-2025
9 companies · $147 in 2025
The $147 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $29.00 · 2021: $31.30 · 2022: $121 · 2023: $109 · 2024: $197 · 2025: $147.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $453.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $452.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $135.93 | 2021-2025 | Abilify Maintena, Abilify Asimtufii |
| Alkermes, INC. | $126.24 | 2022-2025 | Aristada, Lybalvi |
| Abbvie INC. | $103.61 | 2022-2025 | |
| Teva Pharmaceuticals USA, INC. | $84.47 | 2024-2025 | Uzedy, Austedo Xr |
| Indivior INC. | $57.57 | 2022-2023 | Perseris |
| E.R. Squibb & Sons, L.L.C. | $40.81 | 2024-2025 | Cobenfy |
| Neurocrine Biosciences, INC. | $30.64 | 2021-2024 | Ingrezza |
| Sunovion Pharmaceuticals INC. | $29.00 | 2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $25.66 | 2024 | Caplyta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Long listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.